Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdozokitug + Toripalimab + Bevacizumab in Advanced Hepatocellular Carcinoma
NCT06679985Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of casdozokitug in hepatocellular carcinoma (HCC) (3 arms). Primary endpoints: Number of Participants with Treatment-emergent Adverse Events and Objective Response Rate by Investigator Review According to RECIST v1.1. Started Dec 2024; status: active, not recruiting.
02
Drugs
casdozokitug
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06679985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679985.